Executives at Edwards Lifesciences Corp Execute Stock Transactions
| Reporter Name | Relationship | Type | Amount | SEC Filing |
|---|---|---|---|---|
| Stone Heisz Leslie | Director | Sell | $435,370 | Form 4 |
| Lippis Daniel J. | CVP, JAPAC | Sell | $38,170 | Form 4 |
| Bobo Donald E Jr | CVP,Strategy/Corp Development | Sell | $492,363 | Form 4 |
| Ullem Scott B. | CVP, Chief Financial Officer | Sell | $852,271 | Form 4 |
Leslie Stone Heisz, a Director at Edwards Lifesciences Corp, sold 5,739 shares of Common Stock on February 13, 2025, at a weighted average price of $75.8618, totaling $435,370. Following the transaction, Heisz directly owns 30,035 shares of the company.
Daniel J. Lippis, CVP, JAPAC of Edwards Lifesciences Corp, sold 500 shares on February 13, 2025, at a price of $76.34 per share, totaling $38,170. Post-sale, Lippis directly owns 23,189 shares. The sale was executed under a Rule 10b5-1 trading plan adopted on December 11, 2023.
Bobo Donald E Jr, CVP of Strategy/Corp Development at Edwards Lifesciences Corp, sold 6,500 shares on February 13, 2025, with a weighted average price of $75.7402, totaling $492,363. Following these transactions, Bobo directly owns 46,935 shares and indirectly owns 173,878 shares through a 401(k) and by trust.
Scott B. Ullem, the Chief Financial Officer of Edwards Lifesciences Corp, sold 11,250 shares on February 13, 2025, at a weighted average price of $75.7575, totaling $852,271. After the sale, Ullem directly owns 30,561 shares and indirectly owns 266,318 shares through a trust.